Back to top
more

IDEAYA Biosciences (IDYA)

(Delayed Data from NSDQ)

$40.32 USD

40.32
596,585

-0.18 (-0.44%)

Updated May 20, 2024 04:00 PM ET

After-Market: $40.36 +0.04 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for IDYA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

IDEAYA Biosciences, Inc. [IDYA]

Reports for Purchase

Showing records 121 - 140 ( 167 total )

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 121

01/06/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 122

01/05/2021

Daily Note

Pages: 3

Phase 1 Combination Study Begins as First Patient Dosed With IDE196 and Xalkori

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 123

01/05/2021

Company Report

Pages: 6

First Patient Dosed in Phase 1 Study of IDE196 + Crizotinib in MUM

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 124

11/13/2020

Daily Note

Pages: 13

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 125

11/13/2020

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 126

11/13/2020

Company Report

Pages: 7

Q3 Financials; Robust Synthetic Lethality Pipeline Coming into Focus

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 127

11/13/2020

Company Report

Pages: 7

3Q20 Update - Strong Cash Position and Robust Pipeline Execution

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 128

11/13/2020

Company Report

Pages: 7

3Q20 Update - Strong Cash Position and Robust Pipeline Execution

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 129

11/13/2020

Company Report

Pages: 8

3Q20 Results; IND Filing for the First Synthetic Lethality Program Drug, IDE397, Projected for December 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 130

10/22/2020

Daily Note

Pages: 3

Partnership Strengthens Synthetic Lethality Program

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 131

10/16/2020

Daily Note

Pages: 10

Healthcare- Key Takeaways from Our Talk Series

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 132

10/07/2020

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 133

10/06/2020

Company Report

Pages: 45

Initiating OUTPERFORM with $21 PT; Lethal Precision Medicine

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 100.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 134

10/05/2020

Company Report

Pages: 5

Join Our Management Call Tomorrow at 12PM ET

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 135

10/01/2020

Industry Report

Pages: 7

Next Week Our Mgmt Talk Series Features

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 136

09/24/2020

Daily Note

Pages: 3

IDEAYA Clinical Collaboration With Pfizer Expanded to Include Combination of IDE196 With Xalkori

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 137

09/24/2020

Daily Note

Pages: 7

Healthcare- Coming Up Next Week

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 138

09/10/2020

Industry Report

Pages: 3

Upcoming Webinars to Discuss Near-Term Catalysts with Our Covered Companies

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 139

08/13/2020

Company Report

Pages: 8

2Q20 Results; First Synthetic Lethality Candidate Could Reach the Clinic in 1H21

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 140

08/12/2020

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party